 BASEL, Switzerland--BUSINESS WIRE--Novaremed AG, a privately held clinical-stage biopharmaceutical company, announces the acquisition of Metys Pharmaceuticals AG Metys, including all of its development programs, in an all-share transaction. The acquisition broadens Novaremeds existing pipeline by adding both clinical and preclinical development projects based on an innovative approach for non-opioid chronic pain treatment, the Companys focus area. Moreover, it enables Novaremed to target 